Epanova® for Lowering Very High Triglycerides II (EVOLVE II)

Hypertriglyceridemia Clinical Trial

— EVOLVEII  

Official title:

A 12-Week, Randomized, Double-Blind, Olive Oil-Controlled Phase 3 Study to Assess the Efficacy and Safety of EPANOVA™ in Subjects With Severe Hypertriglyceridemia (EVOLVE II)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02009865
• Other study ID #: D5880C00001
• Secondary ID: OM-EPA-011
• Status: Completed
• Phase: Phase 3
• Start date: December 16, 2013
• Est. completion date: December 23, 2014

Study information

• Verified date: August 2019
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a double-blind, randomized, olive oil-controlled study to investigate the efficacy and safety of Epanova as an adjunct therapy to diet for reduction of TG levels in subjects with severe hypertriglyceridemia. The study consists of an approximately 8-week screening period that includes a diet and lifestyle stabilization and washout period and a 12-week treatment period.

Description:

[During the screening period and treatment period, all visits are to be within ±3 days of the scheduled time.]

Screening Period:

Visit 1 will occur at Week -8 for subjects requiring washout and/or statin, cholesterol-absorption inhibitor (CAI), or statin-CAI stabilization. This includes subjects who:

• Were previously on omega-3 drugs/supplements;

• Require adjustment to or addition of permitted statins, CAI, or statin-CAI combination;

• Have not been on a permitted stable dose of statin, CAI, or statin-CAI combination for at least 4 weeks prior to Visit 1; and/or

• Need to washout of bile acid sequestrants, fibrates, niacin, and other supplements known to alter lipid metabolism.

For these subjects who require washout and/or statin, CAI, or statin-CAI stabilization, at Visit 1 (Week -8) screening procedures will be performed. Subjects will return at Visit 1a (Week -2) for their first qualifying lipid measurement.

For subjects not requiring washout, Visit 1 will occur at Week -2. All screening procedures will be performed at this visit including the first qualifying lipid measurement.

At Visit 2 (Week -1), all subjects will return for their second lipid qualifying measurement. If at Visit 2 the subject does not have an average TG ≥500 mg/dL (6 mmol/L) and <2500 mg/dL (28 mmol/L), the TG measurement may be repeated one additional time after Visit 2 (Visit 2a). The subject's qualifying measurement would be the average of Visit 1 or 1a + Visit 2 + Visit 2a (repeat measurement).

To be eligible for randomization, the subject must have a qualifying TG ≥500 mg/dL (6 mmol/L) and <2500 mg/dL (28 mmol/L). Of the total number of subjects, approximately 50% will have a qualifying TG >885 mg/dL (10 mmol/L) and <2500 mg/dL (28 mmol/L). Once approximately 50% of the total subjects has been reached for each TG group, enrollment of subjects with that specific TG criterion will stop. Subjects will be equally allocated to each treatment group.

[At the screening visit, all subjects will receive counseling regarding the National Cholesterol Education Program (NCEP) Therapeutic Lifestyle Changes (TLC) diet and will receive basic instructions on how to follow this diet. See Appendix C.]

Treatment Period:

At Visit 3 (Week 0), approximately 116 subjects will be randomized in a 1:1 ratio to receive daily olive oil 2 g or Epanova 2 g. Subjects will be stratified by lipid-altering drugs to ensure a balanced allocation of subjects who are users and non-users of the following permitted lipid-altering drugs in each treatment group: statin, CAI, or statin-CAI combination. During the treatment period, subjects will return to the site at Visit 4 (Week 6), Visit 5 (Week 10), and Visit 6 (Week 12) for efficacy and safety evaluations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 379
• Est. completion date: December 23, 2014
• Est. primary completion date: December 23, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 130 Years

Eligibility

Inclusion Criteria:

1. Understanding of the study procedures, willingness to adhere to the study schedule, and agreement to participate in the study by giving written informed consent prior to screening;

2. Willing to use an appropriate and effective method of contraception;

3. Qualifying (average of Visit 1 or 1a + Visit 2 + Visit 2a [repeat measurement]) serum TG =500 mg/dL (6 mMol/L) and <2500 mg/dL (28 mMol/L);

4. Body mass index =20 kg/m2;

5. Untreated dyslipidemia or dyslipidemia treated with a statin, CAI, or statin-CAI combination that has been stable for 6 weeks prior to randomization; and

6. Willingness to maintain current physical activity level and follow the TLC diet throughout the study.

Exclusion Criteria:

1. Allergy or intolerance to omega-3 fatty acids, omega-3-acid ethyl esters, or fish;

2. Known lipoprotein lipase impairment;

3. Known non-responder to omega-3 or fenofibrate therapy;

4. Use of any prescription medications containing EPA and/or DHA (eg, Lovaza® or Vascepa®) within 8 weeks prior to randomization. Up to 1 g capsule/day of an omega-3 dietary supplement will be permitted;

5. Unable to discontinue use of bile acid sequestrants, fibrates or niacin (other than niacin-containing vitamins <200 mg), or any supplement used to alter lipid metabolism including but not limited to dietary fiber supplements, red rice yeast supplements, garlic supplements, soy isoflavone supplements, sterol/stanol products, or policosanols at screening;

6. Use of tamoxifen, estrogens, or progestins that has not been stable for >4 weeks at screening or is unstable prior to randomization;

7. Use of oral or injected corticosteroids or anabolic steroids prior to randomization;

8. History of hospitalization for pancreatitis in the last 5 years;

9. Uncontrolled diabetes (hemoglobin A1c [HbA1c] >10%);

10. Uncontrolled hypothyroidism or thyroid-stimulating hormone (TSH) >5 mIU/L;

11. History of cancer (other than basal cell carcinoma) in the past 2 years;

12. Cardiovascular event (ie, myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient heart attack, unstable congestive heart failure requiring a change in treatment), revascularization procedure or vascular surgery within 6 months of randomization;

13. Use of simvastatin 80 mg or Vytorin 10/80 mg;

14. Recent history (within 6 months of randomization) of significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal, or immunologic disease;

15. Poorly controlled hypertension (systolic blood pressure =180 mmHg and/or diastolic blood pressure =110 mmHg);

16. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × the upper limit of normal (ULN); if ALT/AST is >3 × ULN, the levels have been stable for 3 months and are <5 × ULN;

17. Exposure to any investigational product within 4 weeks of randomization; or

18. Any condition or therapy which, in the opinion of the Investigator, might pose a risk to the subject or make participation in the study not in the subject's best interest.

Related Conditions & MeSH terms

• Hypertriglyceridemia

Intervention

Drug:
• Epanova
Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
• Olive Oil
Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.

Locations

Country	Name	City	State
Canada	Research Site	Chicoutimi	Quebec
Czechia	Research Site	Hradec Kralova
Czechia	Research Site	Trutnov
Czechia	Research Site	Zlín
Denmark	Research Site	Esbjerg
Denmark	Research Site	Gentofte
Denmark	Research Site	Herlev
Denmark	Research Site	Viborg
Hungary	Research Site	Baja
Hungary	Research Site	Balatonfured
Hungary	Research Site	Budapest
Hungary	Research Site	Debrecen
Hungary	Research Site	Debrecen
Hungary	Research Site	Sátoraljaújhely
Hungary	Research Site	Székesfehérvár
Hungary	Research Site	Szikszó
Netherlands	Research Site	Alkmaar
Netherlands	Research Site	Amsterdam
Russian Federation	Research Site	Barnaul
Russian Federation	Research Site	Ekaterinburg
Russian Federation	Research Site	Kemerovo
Russian Federation	Research Site	Moscow
Russian Federation	Research Site	Moscow
Russian Federation	Research Site	Saint Petersburg
Russian Federation	Research Site	Tomsk
United States	Research Site	Addison	Illinois
United States	Research Site	Bristol	Tennessee
United States	Research Site	Cincinnati	Ohio
United States	Research Site	Cincinnati	Ohio
United States	Research Site	Columbus	Ohio
United States	Research Site	Houston	Texas
United States	Research Site	Katy	Texas
United States	Research Site	Kettering	Ohio
United States	Research Site	Los Angeles	California
United States	Research Site	Louisville	Kentucky
United States	Research Site	Lyndhurst	Ohio
United States	Research Site	Oklahoma City	Oklahoma
United States	Research Site	Orangeburg	South Carolina
United States	Research Site	Philadelphia	Pennsylvania
United States	Research Site	Saint Petersburg	Florida

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Countries where clinical trial is conducted

United States,  Canada,  Czechia,  Denmark,  Hungary,  Netherlands,  Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent Change in Triglyceride for All Subjects	This primary endpoint was tested in parallel together with the first of the secondary endpoints, each at 0.025 Type I error rate.	From Baseline to Week 12 Endpoint
Secondary	Percent Change in Triglycerides for Subjects With at Least 1 Qualifying Triglyceride >885 mg/dL	This first secondary endpoint in subjects with at least 1 qualifying triglyceride >885 mg/dL was tested in parallel together with the primary endpoint, each at 0.025 Type I error rate.	From Baseline to Week 12 Endpoint
Secondary	Percent Change in Non-High-Density Lipoprotein Cholesterol (mg/dL)	This secondary endpoint, together with the 3rd. and 4th secondary ones, was treated as the core secondary, and the p value from the hypothesis test on its treatment comparison was adjusted by using Hommel's procedure.	From Baseline to Week 12 Endpoint
Secondary	Percent Change in High-Density Lipoprotein Cholesterol (mg/dL)	This secondary endpoint, together with the 2nd. and 4th. secondary ones, was treated as the core secondary, and the p value from the hypothesis test on its treatment comparison was adjusted by using Hommel's procedure.	From Baseline to Week 12 Endpoint
Secondary	Percent Change in Triglyceride(mg/dL) in Subjects With Biochemically Defined Fredrickson Type V (Triglyceride/Very-Low-Density Lipoprotein Cholesterol =6)	This secondary endpoint in subjects with Biochemically Defined Fredrickson Type V (Triglyceride/Very-Low-Density Lipoprotein Cholesterol =6), together with the 2nd. and 3rd.secondary ones, was treated as the core secondary, and the p value from the hypothesis test on its treatment comparison was adjusted by using Hommel's procedure.	From Baseline to Week 12 Endpoint